IMA ImageneBio (IMA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001835579
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
14
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about IMA
Insiders, 180 days
-$17.3K net sold
1 seller · 0% of sales under a 10b5-1 plan
ImageneBio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ImageneBio, Inc. insiders sold a net $17.3K of stock across 5 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 16, 2026.
- The trade is 2.7% of the 55,582 shares held after it.
- No other insider sold within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Lally Robert B sold about $8.1K of IMA on Jul 17, 2026; 14 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.9% of the 57,107 shares held after it.
- No other insider sold within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Lally Robert B sold about $9.2K of IMA on Jul 16, 2026, the largest insider sale at the company on our record; 14 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 16,000 shares held after it.
- No other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SLATTERY JOSEPH P bought about $95.8K of IMA on Dec 24, 2025; 14 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 29.0% of the 287,885 shares held after it.
- 1 other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bonita David P bought about $2.5M of IMA on Jul 25, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 58.8% of the 454,982 shares held after it.
- 1 other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stampacchia Otello bought about $8.0M of IMA on Jul 25, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$17.3K over 180 days
more than 60% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
14 funds bought in last quarter
below 75% of Pharma & Biotech
Revenue
-77.1% year over year
below 86% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.6% of the float short (float per yahoo 2026-10-26) · 1.9 days to cover · settled 2026-09-30
below 84% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch IMA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-45.2%12M
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IMA: institutional holders (13F)
13F holdings, latest reported quarter
1,110,002 sh
$6.5M
917,692 sh
$5.4M
909,269 sh
$5.4M
781,599 sh
$4.6M
455,361 sh
$2.7M
Congress trades in IMA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Omega Fund VI, L.P.
Activist 13D · 2026-04-21
8.4%
Omega Fund VI GP, L.P.
Activist 13D · 2026-04-21
8.4%
Omega Fund VI GP Manager, Ltd.
Activist 13D · 2026-04-21
8.4%
Claudio Nessi
Activist 13D · 2026-04-21
8.4%
Otello Stampacchia
Activist 13D · 2026-04-21
8.4%
IMA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
IMA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$157.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$10.5K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$180.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$309.6K position · as of 2026-06-30
0.0%
Total Stock Market Index Trust
$2.6K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$24.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $17.3K sold by insiders over 180 days, 14 funds added last quarter. Each figure is a federal filing, dated the day it went public.
IMA financials
Revenue growth
-77.1%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$800.0K
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM IMA
| FY Dec 2025 | $800.0K |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $9.2M |
| FY Dec 2022 | $15.6M |
| FY Dec 2021 | $31.0M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $800.0K |
| Dec 2024 | $0 |
| Sep 2024 | $3.5M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM IMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -744.1% |
| FY Dec 2022 | -440.3% |
| FY Dec 2021 | -110.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -759.6% |
| Dec 2024 | n/a |
| Sep 2024 | -90.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$53.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IMA
| FY Dec 2025 | -$48.3M |
| FY Dec 2024 | -$21.7M |
| FY Dec 2023 | -$80.2M |
| FY Dec 2022 | -$75.5M |
| FY Dec 2021 | -$62.0M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term 2024-12-31 (18 months older than the period end) plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity IMA
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.01x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-49.56x
TTM operating cash flow over long-term 2024-12-31 (18 months older than the period end) plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt IMA
| FY Dec 2025 | -45.09x |
| FY Dec 2024 | -2.49x |
| FY Dec 2023 | -83.94x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -49.56x |
| Mar 2026 | -52.23x |
| Dec 2025 | -45.09x |
| Sep 2025 | -41.57x |
| Jun 2025 | -1.13x |
| Mar 2025 | -1.20x |
| Dec 2024 | -2.49x |
| Sep 2024 | -41.75x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity IMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -653.5% |
| FY Dec 2022 | -38.8% |
| FY Dec 2021 | -63.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -3,957% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-37.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IMA
| FY Dec 2025 | -53.7% |
| FY Dec 2024 | -35.2% |
| FY Dec 2023 | -37.4% |
| FY Dec 2022 | -32.7% |
| FY Dec 2021 | -16.4% |
| Jun 2026 | -37.7% |
| Mar 2026 | -37.3% |
| Dec 2025 | -53.7% |
| Sep 2025 | -27.9% |
| Jun 2025 | -15.3% |
| Mar 2025 | -13.4% |
| Dec 2024 | -35.2% |
| Sep 2024 | -28.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital IMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-44.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IMA
| FY Dec 2025 | -69.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -45.9% |
| FY Dec 2022 | -38.2% |
| FY Dec 2021 | -18.9% |
| Jun 2026 | -44.6% |
| Mar 2026 | -43.3% |
| Dec 2025 | -69.0% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -34.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing IMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$47.6M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value IMA
| FY Dec 2025 | -$16.3M |
| FY Dec 2024 | $946.2M |
| FY Dec 2023 | $1.0B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$27.1M |
| Mar 2026 | -$19.1M |
| Dec 2025 | -$16.3M |
| Sep 2025 | $291.2M |
| Jun 2025 | $726.3M |
| Mar 2025 | $713.0M |
| Dec 2024 | $946.2M |
| Sep 2024 | $957.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-115.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield IMA
| FY Dec 2025 | -62.5% |
| FY Dec 2024 | -2.3% |
| FY Dec 2023 | -7.0% |
| FY Dec 2022 | -6.5% |
| FY Dec 2021 | -1.1% |
| Jun 2026 | -79.6% |
| Mar 2026 | -99.9% |
| Dec 2025 | -62.5% |
| Sep 2025 | -11.3% |
| Jun 2025 | -1.3% |
| Mar 2025 | -1.4% |
| Dec 2024 | -2.3% |
| Sep 2024 | -4.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing IMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $800.0K | $3.5M | $9.2M | $15.6M |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M |
| Net income | -$45.3M | -$36.6M | -$68.2M | -$68.8M |
| EPS (diluted) | -9.64 | -22.10 | -1.63 | -1.90 |
| Operating cash flow | -$47.8M | -$21.3M | -$79.7M | -$74.1M |
| Cash | $94.5M | $12.1M | $119.9M | $59.9M |
| Long-term debt | n/a | $1.1M | $950.0K | n/a |
| Buybacks | n/a | n/a | $663.0K | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
IMA Stock Sonar score 6/7 axes
Find similar shapesCompareIMA ranks highest on profitability (55th percentile) and financial health (45th), and lowest on growth (14th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IMA filings, in plain words
Are ImageneBio insiders buying or selling IMA?
In the 180 days to 2026-10-28, ImageneBio insiders were net sellers, a net $17.3K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, ImageneBio insiders were net sellers of IMA, a net $17.3K across purchases and sales reported on Form 4 by 1 seller. The latest 5% ownership filing is a 13D by Omega Fund VI, L.P., filed 2026-04-21, for 8.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
